Magrolimab, a monoclonal anti-CD47 antibody, demonstrated limited efficacy as a single-agent in AML with no objective responses (stable disease: 73%) (108), but might be more efficacious if added to established combination regimens (discussed below). Here, CD47 is linked to acute myeloid leukemia.